Corpus ID: 23042231

Relative potency of incobotulinumtoxinA vs onabotulinumtoxinA a meta-analysis of key evidence.

@article{Jandhyala2012RelativePO,
  title={Relative potency of incobotulinumtoxinA vs onabotulinumtoxinA a meta-analysis of key evidence.},
  author={R. Jandhyala},
  journal={Journal of drugs in dermatology : JDD},
  year={2012},
  volume={11 6},
  pages={
          731-6
        }
}
  • R. Jandhyala
  • Published 2012
  • Medicine
  • Journal of drugs in dermatology : JDD
Botulinum neurotoxin-A (BoNT-A) has become widely used in aesthetic applications over the past 20 years with several formulations now available. Although widely assumed to be equipotent, recent claims that the original commercial formulation, onabotulinumtoxinA (Botox®/Vistabel®, Allergan UK, Marlow, UK) is more potent than incobotulinumtoxinA (Bocouture®/Xeomin®, Merz Pharma, UK) have raised concerns that clinicians may be persuaded to increase doses to the potential detriment of their… Expand
Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
  • W. Prager
  • Medicine
  • Clinical pharmacology : advances and applications
  • 2013
IncobotulinumtoxinA for Aesthetic Indications: A Systematic Review of Prospective Comparative Trials
Comparison of different consensuses of BTXA in different countries
  • A. Sharova
  • Medicine
  • Journal of cosmetic dermatology
  • 2016
...
1
2
3
...